Multiply Labs Raises $75M to Expand Robotic Drug Manufacturing
Multiply Labs raised $75M Series B led by Dr. Patrick Soon-Shiong and NantWorks to expand robotic systems for automating biologics manufacturing.
The big picture: Multiply Labs raised $75 million in Series B funding to expand its robotic systems for automating manual steps in biologics manufacturing.
Why it matters:
- Scaling production: While AI accelerates drug discovery, manufacturing processes, particularly for advanced biologics, have not kept pace, creating a bottleneck in delivering new therapies.
- Reducing contamination: Many biomanufacturing steps remain manual, increasing the risk of contamination, which can lead to significant costs and production delays for sensitive therapies like cell and gene treatments.
- Bridging the gap: Robotics offers the only viable path to scale the production of complex therapies, ensuring that more patients can access treatments designed by advanced AI.
How it works:
- Autonomous systems: Multiply Labs develops robotic clusters designed to automate timed, repetitive production steps within an enclosed, GMP-compliant environment.
- Seamless integration: The systems are built to work with existing pharmaceutical equipment and manufacturing processes, eliminating the need for new facilities or changes to validated procedures.
- Efficiency gains: The company claims its robotic systems can reduce the cost per dose by 74% and deliver up to 100 times the throughput of manual manufacturing, while continuously learning and adapting.
The catch: The biomanufacturing automation sector is increasingly competitive, with various companies offering solutions. Pharmaceutical firms may face significant upfront investment and the complexities of validating new robotic systems within highly regulated environments, potentially slowing adoption despite the long-term benefits in scalability and contamination control.
Key Facts
- Company: Multiply Labs
- Amount: $75M
- Round: Series B
- Investors: Dr. Patrick Soon-Shiong and NantWorks (co-lead), AstraZeneca, Lingotto, Teradyne, Strange Ventures, Casdin Capital, Lux Capital, Fifty Years, Ora Global, Founders Fund
- Founder: Fred Parietti
- Announced: 2026-10-06
- Sector: Robotic Biologics Manufacturing Automation
- Headquarters: San Francisco, US
Funding Weekly
Every AI funding round we reported last week: the totals, the biggest deals and what they add up to. Weekly · Tuesdays.